This case involved the discovery of the XPO1-ALK fusion and demonstrated that a patient with multiple organ metastases and lung adenocarcinoma harboring an XPO1-ALK fusion mutation responded effectively to brigatinib targeted therapy without serious adverse effects that could cause dosing changes. This evidence concerns the gene XPO1 and lung adenocarcinoma.